Salt Lake City, UT. , May 08, 2018 -- Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-seven cents ($.27) per share of common stock payable on July 6, 2018 to shareholders of record at the close of business on June 15, 2018. This is a 2% increase over the dividend declared in the same quarter of the prior year.
Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD’s website at www.utahmed.com.
Contact: Utah Medical Products, Inc. Crystal Rios (801) 566-1200


Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Google Secures Pentagon AI Deal for Classified Projects
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 



